

## CD200 Protein, Cynomolgus, Recombinant (His)

### General Information

Synonyms:	MOX1;CD200;MOX2;My033;OX-2;MRC;OX2
Protein Construction:	Gln56-Gly257
Species:	Cynomolgus
Expression Host:	HEK293 Cells
Accession:	A0A2K5TQS2
Molecular Weight:	23.66 kDa (predicted). Due to glycosylation, the protein migrates to 45-55 kDa based on Tris-Bis PAGE result.

### QC Testing

Biological Activity:	Cynomolgus CD200 R1, His Tag immobilized on CM5 Chip can bind Cynomolgus CD200, His Tag with an affinity constant of 35.84 nM as determined in SPR assay.
Purity:	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Endotoxin:	< 1.0 EU/ $\mu$ g of the protein as determined by the LAL method.
Formulation:	Lyophilized from a solution filtered through a 0.22 $\mu$ m filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.

### Preparation and Storage

#### Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100  $\mu$ g/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

#### Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

#### Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

### Protein Background

CD200 and its receptors are highly expressed in the lung, on epithelial cells and leukocytes, and emerging evidence links dysregulation of the CD200 pathway with asthma. Moreover, pharmacological modulation of CD200 receptors was shown to improve clinical and inflammatory outcomes of preclinical asthma models.

Reference

Ngwa C, Liu F. CD200-CD200R signaling and diseases: a potential therapeutic target? Int J Physiol Pathophysiol Pharmacol. 2019 Dec 15;11(6):297-309. PMID: 31993106; PMCID: PMC6971504.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481